92 related articles for article (PubMed ID: 1358419)
1. Proceedings from a symposium of basic research on ipriflavone (Osten). Yokohama, Japan. January 18, 1992.
Calcif Tissue Int; 1992; 51 Suppl 1():S1-34. PubMed ID: 1358419
[No Abstract] [Full Text] [Related]
2. Ipriflavone: background.
Gennari C
Calcif Tissue Int; 1997; 61 Suppl 1():S3-4. PubMed ID: 9263607
[No Abstract] [Full Text] [Related]
3. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
4. Ipriflavone: A New Non-Hormonal Therapeutic Agent in Osteoporosis. Satellite symposium proceedings. Florence, Italy, April 24, 1992.
Bone Miner; 1992 Oct; 19 Suppl 1():S1-64. PubMed ID: 1358372
[No Abstract] [Full Text] [Related]
5. [Ipriflavone in the treatment of osteoporosis].
Makita K; Ohta H
Nihon Rinsho; 2002 Mar; 60 Suppl 3():359-64. PubMed ID: 11979930
[No Abstract] [Full Text] [Related]
6. Ipriflavone.
Altern Med Rev; 2000 Jun; 5(3):260-3. PubMed ID: 10869105
[No Abstract] [Full Text] [Related]
7. The effect of ipriflavone treatment on osteoporosis induced by immobilization.
Földes I; Rapcsák M; Szöör A; Gyarmati J; Szilágyi T
Acta Morphol Hung; 1988; 36(1-2):79-93. PubMed ID: 3149863
[TBL] [Abstract][Full Text] [Related]
8. Ipriflavone: an important bone-building isoflavone.
Head KA
Altern Med Rev; 1999 Feb; 4(1):10-22. PubMed ID: 9988779
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
10. [Isoflavones and calcified tissues].
Sukmanskiĭ OI
Usp Fiziol Nauk; 2002; 33(2):83-94. PubMed ID: 12004580
[TBL] [Abstract][Full Text] [Related]
11. Isoflavones, protein, and bone.
Sebastian A
Am J Clin Nutr; 2005 Apr; 81(4):733-5. PubMed ID: 15817845
[No Abstract] [Full Text] [Related]
12. [Overview of clinical studies with ipriflavone].
Attila BK
Acta Pharm Hung; 1995 Nov; 65(6):223-8. PubMed ID: 8742630
[TBL] [Abstract][Full Text] [Related]
13. Effect of ipriflavone on accessory sexual organs and bone metabolism in male rats.
Yamazaki I
Bone Miner; 1987 Jul; 2(4):271-80. PubMed ID: 3505762
[TBL] [Abstract][Full Text] [Related]
14. Combination of genistin and fructooligosaccharides prevents bone loss in ovarian hormone deficiency.
Hooshmand S; Juma S; Arjmandi BH
J Med Food; 2010 Apr; 13(2):320-5. PubMed ID: 20132047
[TBL] [Abstract][Full Text] [Related]
15. [A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
Bossányi A; Bucsi L
Magy Traumatol Orthop Helyreallito Seb; 1989; 32(2):109-15. PubMed ID: 2570885
[TBL] [Abstract][Full Text] [Related]
16. [Place of ipriflavone in the therapy of osteoporosis].
Zsuzsanna B
Acta Pharm Hung; 1995 Nov; 65(6):229-32. PubMed ID: 8742631
[TBL] [Abstract][Full Text] [Related]
17. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
18. Effects of ipriflavone and estriol on postmenopausal osteoporotic changes.
Hanabayashi T; Imai A; Tamaya T
Int J Gynaecol Obstet; 1995 Oct; 51(1):63-4. PubMed ID: 8582523
[No Abstract] [Full Text] [Related]
19. Prevention of retinoic acid-induced osteoporosis in mice by isoflavone-enriched soy protein.
Yang J; Wu N; Peng J; Yang X; Guo J; Yin S; Wang J
J Sci Food Agric; 2016 Jan; 96(1):331-8. PubMed ID: 25645024
[TBL] [Abstract][Full Text] [Related]
20. [Ipriflavone].
Kitatani K; Morii H
Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
